Endologix Disputes Alleged Patent Infringement
Endologix, Inc. (NASDAQ: ELGX) responded to the Bard Peripheral Vascular, Inc. lawsuit filed against Endologix in the United States District Court of Arizona. The Bard Peripheral lawsuit alleges that Endologix's proprietary high density ePTFE graft material, which is used for the Powerlink(R) System, infringes on Bard Peripheral's "Prosthetic Vascular Graft" patent.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.